Clinical trial
Efficacy Safety Study Comparing 2 Doses of NVP After Initiating…
NCT00476853 · The HIV Netherlands Australia Thailand Research Collaboration, Other · Completed
Key facts
| NCT number | NCT00476853 |
|---|---|
| Title | Efficacy Safety Study Comparing 2 Doses of NVP After Initiating Rifampin-containing TB Therapy |
| Official title | A 48 Week, Randomized, Open-label, 2 Arm Study to Compare the Efficacy, Safety and Tolerability of HAART Containing Nevirapine 400mg/Day Versus Nevirapine 600 mg/Day in HIV-1 Infected Patients Started at 2-6 Weeks After Initiating Rifampin Containing Antituberculous Therapy |
| Lead sponsor | The HIV Netherlands Australia Thailand Research Collaboration, Other |
| Collaborators | other sponsors:Japanese MOPH Labor and Welfare Thai MOPH Thai GPO Bamrasnaradura Infectious Diseases Institute Chiang Rai Hospital King Chulalongkorn Memorial Hospital Central General Chest Institute… |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections, Tuberculosis |
| Intervention type | Drug |
| Interventions | HAART containing nevirapine |
| Enrollment | 42 |
| Start date | Oct 1, 2005 |
| Primary completion | Sep 1, 2008 |
| Completion | Dec 1, 2009 |
| First posted | May 22, 2007 |
| Last update posted | Jul 17, 2020 |
| Countries | Thailand |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: